ストックスクリーナーアプリを入手
45.60
1.81%
0.81
アフターアワーズ：
45.54
-0.06
-0.13%
前日終値:
$44.79
開ける：
$45.21
24時間の取引高:
3.57M
Relative Volume:
1.12
時価総額：
$12.44B
収益：
$2.17B
当期純損益:
$521.27M
株価収益率:
25.76
EPS:
1.77
ネットキャッシュフロー:
$633.79M
1週間 パフォーマンス:
+2.54%
1か月 パフォーマンス:
+4.76%
6か月 パフォーマンス:
+40.83%
1年 パフォーマンス:
+98.61%
1日の値動き範囲:
$44.83
$45.72
1週間の範囲:
$43.86
$45.75
52週間の値動き範囲:
$22.80
$49.62
Exelixis Inc Stock (EXEL) Company Profile
EXEL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
45.60 | 12.21B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-08 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-10-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2024-09-19 | 開始されました | UBS | Neutral |
| 2024-04-11 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 開始されました | BTIG Research | Buy |
| 2023-12-15 | 開始されました | Citigroup | Buy |
| 2023-09-26 | 開始されました | H.C. Wainwright | Buy |
| 2023-08-22 | 繰り返されました | Oppenheimer | Outperform |
| 2023-08-08 | 開始されました | SVB Securities | Market Perform |
| 2023-07-11 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 再開されました | Piper Sandler | Overweight |
| 2023-03-09 | 開始されました | Wells Fargo | Overweight |
| 2023-01-26 | 開始されました | Credit Suisse | Outperform |
| 2022-10-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-11-03 | 再開されました | Jefferies | Buy |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-18 | 再開されました | Goldman | Sell |
| 2021-03-31 | 開始されました | Credit Suisse | Outperform |
| 2021-03-12 | 開始されました | Wolfe Research | Outperform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-13 | 開始されました | SunTrust | Buy |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-03-18 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 開始されました | Goldman | Neutral |
| 2018-09-10 | 開始されました | Morgan Stanley | Underweight |
| 2018-05-11 | 繰り返されました | Needham | Buy |
| 2017-10-17 | 繰り返されました | Needham | Buy |
| 2017-10-17 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-10-16 | 繰り返されました | SunTrust | Buy |
| 2017-09-22 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-09-12 | 繰り返されました | Needham | Buy |
| 2017-07-14 | 開始されました | SunTrust | Buy |
| 2017-03-31 | 開始されました | Needham | Buy |
| 2017-03-16 | 開始されました | Oppenheimer | Perform |
| 2017-02-28 | ダウングレード | Stifel | Buy → Hold |
| 2016-11-03 | 開始されました | Deutsche Bank | Buy |
| 2016-10-10 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 繰り返されました | Stifel | Buy |
すべてを表示
Exelixis Inc (EXEL) 最新ニュース
EU approves cabozantinib for previously treated neuroendocrine tumors By Investing.com - Investing.com South Africa
Exelixis and Ipsen's Breakthrough Approval of CABOMETYX in Neuroendocrine Tumors: A Game Changer in a High-Growth Oncology Niche - AInvest
(cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire
Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner - MSN
Ipsen wins EU nod for Exelixis cancer drug (EXEL:NASDAQ) - Seeking Alpha
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors - GlobeNewswire Inc.
Citizens JMP Maintains Buy Rating on Exelixis with $50 Price Target - AInvest
Exelixis Gains Analyst Confidence as Cancer Studies Advances - MSN
Exelixis stock poised for Q2 beat on strong script growth, JMP says - Investing.com Canada
What analysts say about Exelixis Inc. stockExceptional growth trajectory - Autocar Professional
Exelixis Advances Cancer Studies with Rising Analyst Confidence - AInvest
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth? - TradingView
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 Earnings - Yahoo Finance
Is Exelixis Inc. a good long term investmentSuperior profit margins - jammulinksnews.com
Earnings Preview: Exelixis to Report Financial Results Post-market on July 28 - 富途牛牛
Exelixis Inc. Stock Analysis and ForecastLightning-fast growth - jammulinksnews.com
Is Exelixis, Inc.'s (NASDAQ:EXEL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - Yahoo Finance
Lobbying Update: $480,000 of EXELIXIS INC. lobbying was just disclosed - Quiver Quantitative
Morgan Stanley Maintains Exelixis(EXEL.US) With Buy Rating, Raises Target Price to $48 - 富途牛牛
Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
Exelixis, Inc. (EXEL) Stock Analysis: Evaluating the 30.6% Revenue Growth and Future Prospects - DirectorsTalk Interviews
What drives Exelixis Inc. stock priceHigh-performance investment picks - jammulinksnews.com
Teva Pharmaceutical Industries Limited shares fall 1.38% intraday after Exelixis, Inc. presents at Lucid Capital Markets. - AInvest
Exelixis Advances Cancer Treatment with New Phase 1 Study of XL309 - The Globe and Mail
Exelixis’s SWOT analysis: zanza trials key to stock’s future growth By Investing.com - Investing.com South Africa
Exelixis’s SWOT analysis: zanza trials key to stock’s future growth - Investing.com
Exelixis Insiders Sell US$12m Of Stock, Possibly Signalling Caution - simplywall.st
Long Term Trading Analysis for (EXEL) - news.stocktradersdaily.com
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings? - The Globe and Mail
Truist Securities raises Exelixis stock price target to $56 on positive outlook - Investing.com Canada
Truist Lifts Price Target on Exelixis to $56 From $55, Keeps Buy Rating - MarketScreener
Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025 - BioSpace
Press Release: Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025 - 富途牛牛
Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why - sharewise.com
Exelixis’ Phase 3 Trial: A New Hope for Renal Cell Carcinoma? - TipRanks
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT) and Exelixis (EXEL) - The Globe and Mail
Barclays Remains a Hold on Exelixis (EXEL) - The Globe and Mail
Assessing Exelixis: Insights From 12 Financial Analysts - Nasdaq
Exelixis cut to sector perform at RBC as cash flows fairly valued - MSN
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Exelixis Inc (EXEL) 財務データ
収益
当期純利益
現金流量
EPS
Exelixis Inc (EXEL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| WYSZOMIERSKI JACK L | Director |
Jun 03 '25 |
Sale |
43.09 |
7,535 |
324,683 |
358,882 |
0.97%
0.22%
大文字化:
|
ボリューム (24 時間):